search
Back to results

Comparison of Relapse Rate After 12 Weeks Verses 20 Weeks Steroid Therapy for the Management of First Episode of Steroid Sensitive Nephrotic Syndrome

Primary Purpose

Steroid-Sensitive Nephrotic Syndrome

Status
Unknown status
Phase
Not Applicable
Locations
Pakistan
Study Type
Interventional
Intervention
Prednisolone
Sponsored by
Shaheed Zulfiqar Ali Bhutto Medical University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Steroid-Sensitive Nephrotic Syndrome focused on measuring Nephrotic Syndrome, steroid response, relapse

Eligibility Criteria

1 Year - 8 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Children 1 to 8 years of age,
  • Diagnose with nephrotic syndrome for the first time
  • Steroid sensitive nephrotic syndrome

Exclusion Criteria:

  • Steroid resistant nephrotic syndrome
  • Steroid dependent nephrotic syndrome
  • Syndromic Children
  • Children with other co morbidities

Sites / Locations

  • Pakistan Institute of Medical SciencesRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Group A

Group B

Arm Description

Steroids will be given for short duration of time i-e 12 weeks

Steroid will be given for longer duration i-e 20 weeks

Outcomes

Primary Outcome Measures

Relapse rate
Relapse rete

Secondary Outcome Measures

Full Information

First Posted
January 14, 2021
Last Updated
May 9, 2021
Sponsor
Shaheed Zulfiqar Ali Bhutto Medical University
search

1. Study Identification

Unique Protocol Identification Number
NCT04713410
Brief Title
Comparison of Relapse Rate After 12 Weeks Verses 20 Weeks Steroid Therapy for the Management of First Episode of Steroid Sensitive Nephrotic Syndrome
Official Title
Comparison of Relapse Rate After 12 Weeks Verses 20 Weeks Steroid Therapy for the Management of First Episode of Steroid Sensitive Nephrotic Syndrome: A Randomized Control Trial at Children Hospital, Pakistan Institute of Medical Sciences, Islamabad
Study Type
Interventional

2. Study Status

Record Verification Date
May 2021
Overall Recruitment Status
Unknown status
Study Start Date
December 22, 2020 (Actual)
Primary Completion Date
September 4, 2022 (Anticipated)
Study Completion Date
September 4, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Shaheed Zulfiqar Ali Bhutto Medical University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
All children from 1 to 8 years of age, diagnose with nephrotic syndrome for the first time will be divided into two groups. One group will be given steroids for 12 weeks and other group will receive steroid for 20 weeks. During the 1 years after completion of steroid course patients will be monitor for the episodes of relapse in both group.
Detailed Description
All children from 1 to 8 years of age, diagnose with nephrotic syndrome for the first time, at Pakistan Institute of Medical Sciences, Islamabad, from December 2020 to December 2022 will be included in the study. Sample size was calculated by using WHO sample size calculator keeping level of significance 5%, power of test 90%, P1 21.6%7 and P2 59.3%8. The sample size is turned out to be 34 patients in each group with total of 68 patients. The patients fulfilling the inclusion criteria will be registered at our nephrology clinic. Patients' bio data along with history and examination will be recorded on a proforma. They will be divided in two groups designated as A and B. Group A will receive steroid for 12 weeks and group B for 20 weeks. For group A regimen will be to administer prednisolone as a single dose of 60 mg/m2 once daily for 6 weeks, then 40 mg/m2 on alternate day for another 6 weeks and then stop. For group B prednisolone will be given as a single dose of 60 mg/m2 once daily for 6 weeks, then 40 mg/m2 on alternate day for another 6 weeks with tapering of 25% of alternate day dose fortnightly. Outcome will be measured in terms of number of relapses in the subsequent 1 years after stopping steroids. For treatment of relapse Prednisolone will be given in the dose of 60 mg/m2 once daily till urine protein is negative or trace for 3 consecutive days, then 40 mg/m2 on alternate day for 1 month then stop. In case of frequent relapses and steroid dependent cases, relapses will be treated as follows; prednisolone 60 mg/m2 on alternate day till urine protein will be negative for 5days then 40 mg/m2 on alternate day for 1 month then with tapering at the rate of 5 mg fortnightly. Children with congenital and infantile nephrotic syndrome, persistent hypertension, gross haematuria, family history of nephrotic syndrome and age below 1 year and above 8 years will be excluded from study. After approval of study from ethical review board, informed consent will be taken from parents. The data obtained will be analyzed using SPSS version 20. The t test will be applied for comparison of mean and chi sqare test for comparison of percentages. The p value less than .05 will be taken as significant.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Steroid-Sensitive Nephrotic Syndrome
Keywords
Nephrotic Syndrome, steroid response, relapse

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
68 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Group A
Arm Type
Experimental
Arm Description
Steroids will be given for short duration of time i-e 12 weeks
Arm Title
Group B
Arm Type
Active Comparator
Arm Description
Steroid will be given for longer duration i-e 20 weeks
Intervention Type
Drug
Intervention Name(s)
Prednisolone
Intervention Description
Regimen will be to administer prednisolone as a single dose of 60 mg/m2 once daily for 6 weeks, then 40 mg/m2 on alternate day.
Primary Outcome Measure Information:
Title
Relapse rate
Description
Relapse rete
Time Frame
2 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
1 Year
Maximum Age & Unit of Time
8 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Children 1 to 8 years of age, Diagnose with nephrotic syndrome for the first time Steroid sensitive nephrotic syndrome Exclusion Criteria: Steroid resistant nephrotic syndrome Steroid dependent nephrotic syndrome Syndromic Children Children with other co morbidities
Facility Information:
Facility Name
Pakistan Institute of Medical Sciences
City
Islamabad
State/Province
Capital
ZIP/Postal Code
44000
Country
Pakistan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nighat Haider, FCPS
Phone
03212125768
Email
nighathaider@hotmail.com
First Name & Middle Initial & Last Name & Degree
Jai Krishin, FCPS
Phone
03335094933
Email
jkrishin@gmail.com

12. IPD Sharing Statement

Learn more about this trial

Comparison of Relapse Rate After 12 Weeks Verses 20 Weeks Steroid Therapy for the Management of First Episode of Steroid Sensitive Nephrotic Syndrome

We'll reach out to this number within 24 hrs